Search - tctmd.com

Displaying 21 - 40 of 43

Sort: Relevancy | Date

Presentation TCT 2019

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

Presenter: Robert Welsh

September 26, 2019

Presentation TCT 2019

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Presenter: Francesco Franchi

September 26, 2019

Presentation TCT 2019

Insights From SMART CHOICE

Presenter: Joo-Yong Hahn

September 26, 2019

Presentation TCT 2019

Insights From STOP DAPT-2

Presenter: Takeshi Kimura

September 26, 2019

Presentation TCT 2019

Insights From TWILIGHT

Presenter: Usman Baber

September 26, 2019

Presentation TCT 2019

Insights From GLOBAL LEADERS and GLASSY

Presenter: Pascal Vranckx

September 26, 2019

Presentation TCT 2019

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Presenter: Robert Byrne

September 26, 2019

Presentation TCT 2019

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

Presenter: Amit Vora

September 26, 2019

Presentation TCT 2018

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Presenter: George D. Dangas, Germano Di Sciascio, Anne Tavenier

September 21, 2018

Presentation

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

May 21, 2018

Presentation TCTAP 2018

OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients

Presenter: Duk-Woo Park

April 28, 2018

Presentation TCT 2017

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Presenter: Adrian P. Banning, John D. Puskas, Christopher Kelly, MD

October 31, 2017

Presentation TCT 2017

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Presenter: Dominick J. Angiolillo, Marco Valgimigli, Roxana Mehran

October 30, 2017

Presentation TCT 2017

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Presenter: Davide Capodanno, David Hildick-Smith, Marco Zimarino

October 30, 2017

Presentation TCT 2016

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

Presenter: Jonathan M. Hill, Christoph K. Naber, Manel Sabate

November 01, 2016

Presentation TCT 2016

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Presenter: Dimitrios Alexopoulos, Laurent Bonello, Usman Baber

October 31, 2016

Presentation TCT 2016

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Presenter: John A. Bittl, Daniel I. Simon, Patrick W. Serruys

October 30, 2016

Presentation TCT 2016

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Presenter: Deepak L. Bhatt, Christian W. Hamm, Paul A. Gurbel

October 30, 2016

Presentation ACC 2016

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Presenter: Dominick Angiolillo

April 03, 2016

Presentation JIM 2016

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Presenter: Alberto Menozzi

February 11, 2016

Advertisement

Long-Term Antithrombotic Therapy After PCI: How Do I Incorporate COMPASS Into My Practice?

De-Escalation: When and How? — The Role of Platelet Function and Genetic Testing

Insights From SMART CHOICE

Insights From STOP DAPT-2

Insights From TWILIGHT

Insights From GLOBAL LEADERS and GLASSY

Short and Ultrashort DAPT Strategies After Stent Implantation: What Do We Know and Where Are We Going?

Case Introduction: DAPT Dilemma After a Complex PCI in a High Bleeding Risk Patient

TCT-111: Efficacy and Safety of Glycoprotein IIb/IIIa Inhibitors on Top of a Potent P2Y12 Inhibitor in STEMI: A Pre-Specified Sub-Analysis of the ATLANTIC Trial

Trends in P2Y12 Inhibitor Use and Adherence Among Antiplatelet-Naive Patients After PCI, 2008-2016

OPTIMA Trial: P2Y12 Dose Adjustment for East-Asian ACS Patients

TCT 75: Impact of the Timing of P2Y12 Inhibitor Discontinuation Prior to CABG in Patients With Left Main Disease: Results from the EXCEL Trial

Rationale and Studies of P2Y12 Inhibitor Monotherapy

Treatment of Coronary Bifurcations in the Contemporary Era of P2Y12 Inhibitors and "Biologically Active Stents"

Recommendations for P2Y12 Inhibitor Type, Loading and Duration With BRS in Stable CAD and ACS

TCT 6: Simultaneous Impact of Thrombotic and Bleeding Risks on Use of Novel P2Y12 Inhibitors in Contemporary PCI: Results From a Large Single-Center Registry

Rationale and Studies of P2Y12 Inhibitor Monotherapy After DES In Patients In Normal Sinus Rhythm

Transitioning Between Cangrelor and Oral P2Y12 Inhibitors: All the Permutations

Optimal Loading Dose and Delivery of P2Y12 Inhibitors: Should the Loading Dose Be Crushed?

Oral antiplatelet therapy in elderly New P2Y12 inhibitors are the right choice

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content